HER2 and topoisomerase IIα: Useful clinical markers in breast cancer;HER2 et topo-isomérase IIα: Deux marqueurs d'intérêt clinique dans le cancer du sein

Bulletin du Cancer

Volumn 95, Issue 3, 2008, Pages 344-351

  Larsimont, Denis ^a   Durbecq, Virginie ^a   Awada, Ahmad ^a   Di Leo, Angelo ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b Hôpital de Prato   (Italy)

Author keywords

Breast cancer; HER2; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P185; TOPOISOMERASE II ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CLINICAL PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; REVIEW;

EID: 42149126122     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0596     Document Type: Review

References (42)

1. Schechter AL, Stern DL, Vardyanathan L, Decker SJ, Drebin JA, Greene MI. The neu oncogene : an erb-B-related gene encoding a 185 000-Mr-tumor antigen. Nature 1984 ; 312 : 513-6.
2. Olayioye M, Neve RM, Lane HA, Hynes NE. The erb-B signaling network : receptor heterodimerization in development and cancer. EMBO J 2000 ; 19 : 3159-67.
3. Pauletti G, Goldophin W, Press MF, Slamon DJ. Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996 ; 13 : 63-72.
4. Belkacemi Y, Gligorov J, Mauriac L, Azria D. HER-2/neu positive breast cancer : how to prescribe adjuvant trastuzumab (Herceptin)? Bull Cancer 2006 ; 93 : 991-9.
5. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldirsh A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005 ; 353 : 1659-72.
6. Hicks DG, Yoder BY, Pettay J, Swain E, Tarr S, Hartke M, et al. The incidence of topoisomerase II alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification : a fluorescence in situ hybridization study. Hum Pathol 2005 ; 36 : 348-56.
7. Dybdal N, Leiberman G, Andersons, McCune B, Bajamonde A, Cohen RL, et al. Determination of HER-2 gene amplification by fluorescence in situ hybridization and concordance with the clinicals trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005 ; 93 : 3-11.
8. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Ruschoff J, Gutjahr T, et al. Standardization of Her2 testing : results of an international proficiency testing ring study. Mod Pathol 2007 ; 20 : 584-91.
9. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of HER-2/neu alterations in human breast cancer : a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000 ; 18 : 3651-64.
10. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in situ hybridization : a practical alternative for fluorescence in situ hybridization to detect Her2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 ; 157(5) : 1467-72.
11. Arnould L, Denoux Y, Mac Grogan G, Penault-Llorca F, Fiche M, Treilleux I, et al. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER-2 status in breast cancer. Br J Cancer 2003 ; 88 : 1587-91.
12. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004 ; 10 : 4793-8.
13. Vincent-Salomon A, Mac Grogan G, Couturier J, Arnould L, Denoux Y, Fiche M, et al. Calibration of immunohistochemistry for assessment of HER-2 in breast cancer : results of the French multicentre GEFPICS study. Histopathology 2003 ; 42 : 337-47.
14. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, et al. Polysomy 17 in HER2/neu status elaboration in breast cancer : effect on daily practice. Clin Cancer Res 2005 ; 11 : 4393-9.
15. Hofmann MJ, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr, et al. Central HER-2 IHC and FISH analysis in a trastuzumab (Herceptine®) phase II monotherapy study : assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008 ; 61(1) : 89-94.
16. Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat R, Lespagnard L, et al. Correction for chromosome 17 is critical for the determination of true HER-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006 ; 5 : 2572-9.
17. Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER-2-positive breast cancer. ASCO Annual Meeting Proceedings 2007 ; 25 : 512.
18. Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, et al. CALGB 150002 : Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER-2 + and HER-2- metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings 2007 ; 25 : 1009.
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guidelines. Recommandations for human epidermal growth factors receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007 ; 131 : 18-43.
20. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002 ; 13 : 1036-43.
21. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, et al. HER-2 status in patients with breast carcinoma is not modified by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002 ; 94 : 2169-73.
22. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2006 ; 101 : 9393-8.
23. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remain sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004 ; 10 : 3815-24.
24. Dieras V, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P. Trastuzumab (Herceptin) and breast cancer : mechanisms of resistance. Bull Cancer 2007 ; 94 : 259-66.
25. Sàes P, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95 HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006 ; 12 : 424-31.
26. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER-2, a truncated form of HER-2 receptor, and response to anti HER-2 therapies in breast cancer. J Natl Cancer Inst 2007 ; 99 : 628-38.
27. Ginestier C, Adelaide J, Goncalves A, Repellini L, Sircoulomb F, Letessier A, et al. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007 ; 26 : 7163-9.
28. Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, et al. Phosphorylated HER-2 tyrosine kinase and HER-2/neu gene amplification as predictive factors of response to Trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007 ; 43 : 725-35.
29. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting efficacy of anthracyclines in breast cancer : are we in the end of the beginning? Clin Breast Cancer 2003 ; 4 : 179-86.
30. Jarvinen T, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999 ; 26 : 142-50.
31. Olsen KE, Knudsen H, Rasmussen BB, Balslew E, Knoop A, Ejlertsen B, et al. Amplification of HER-2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH. Acta Oncol 2004 ; 43 : 35-42.
32. Jarvinen T, Tanner M, Rantanen V, Barlund M, Borg A, Grenmann S, et al. Amplification and deletion of topoisomerase IIalpha associate with erbB-2 amplification and affect sensitivity to topoisomerase IIalpha inhibitor doxorubicin in breast cancer. Am J Pathol 2000 ; 156 : 839-47.
33. Durbecq V, Desmedt C, Paesmans M, Cardoso F, Di Leo A, Mano M, et al. Correlation between topoisomerase II alpha gene amplification and protein overexpression in HER-2 amplified breast Cancer. Int J Oncol 2004 ; 25 : 1473-9.
34. Adachi N, Nomoto M, Kohnok K, Koyama H. Cell cycle regulation of the DNA topoisomerase II alpha promotor is mediated by proximal CCAAT bases : possible involvement of acetylation. Gene 2000 ; 245 : 49-57.
35. Stacey DW, Hitomi M, Chn G. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Mol Cell Biol 2000 ; 20 : 9127-37.
36. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, et al. HER-2 and topo-isomerase II alpha as predictive markers in a population of node positive breast cancer patients randomly treated with adjuvant CMF or epirubicin. Ann Oncol 2001 ; 12 : 1081-9.
37. Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, et al. Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single agent doxorubicin or single agent docetaxel. Mol Cancer Ther 2004 ; 3 : 1207-14.
38. O'Malley FP, Chia S, Tu D, Shepherd LE, Levure MN, Huntsmann D, et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer. Breast Cancer Res Treat 2006 ; 100(Suppl 1) ; (p518).
39. Mo YY, Beck WT. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res 1997 ; 9 : 193-204.
40. Ernst AI, Saltermann A, Sigrest JA, Widmer L, Gasser SM, Stabel RA. Ectopic expression of human topoisomerase II alpha, fragments and etoposide resistance in mamalian cells. Int J Cancer 2000 ; 88 : 99-107.
41. Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, et al. Correlation between complete response to anthracycline-based chemotherapy and topo-isomerase II alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004 ; 24 : 201-9.
42. Buron C, Doz M, Salomon AV, Couturier J, Beuzeboc P, Livartowski A. Reflexion on innovation diffusion factors : the case of Herceptin. Bull Cancer 2007 ; 94 : 297-306.